This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.
Gazyva's gains came despite increased competition in the CLL market from drugs such as AbbVie/Johnson &Johnson's Imbruvica (ibrutinib) and Gilead Science's Zydelig (idelalisib) and a failed trial
failed a B-cell receptor pathway inhibitor such as AbbVie and Johnson &Johnson's Imbruvica (ibrutinib) or Gilead Science's Zydelig (idelalisib), or both chemo-immunotherapy and a B-cell receptor
cell receptor pathway inhibitor therapy such as Johnson &Johnson's BTK inhibitor Imbruvica (ibrutinib) or Gilead Sciences' Zydelig (idelalisib).
EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has now confirmed that Zydelig (idelalisib) could cause serious illness, including Pneumocystis jirovecii pneumonia.
market share with other new CLL drugs such as Johnson &Johnson's Imbruvica (ibrutinib) and Gilead Sciences' Zydelig (idelalisib).
Venclexta will compete in the market with other new therapies for CLL, including Johnson &Johnson's first-in-class BTK inhibitor Imbruvica (ibrutinib) and Gilead Sciences' PI3 kinase inhibitor Zydelig (idelalisib),
More from news
Approximately 4 fully matching, plus 25 partially matching documents found.